
Bristol Myers Squibb extends Syngene partnership
Bristol Myers Squibb has extended its long-term research collaboration with global CRDMO Syngene until 2035. The expanded agreement broadens the scope of integrated services across the drug development lifecycle spanning discovery, translational sciences, pharmaceutical development and manufacturing, clinical trials, data, and information technology services, to enable seamless progression… Read More















